Assessment of the effects of ISIS 2302, an anti-sense inhibitor of human ICAM-1, on cellular and humoral immunity in mice

Journal of Immunotoxicology

Volumn 3, Issue 4, 2006, Pages 199-211

  Henry, Scott P ^a   Levin, Arthur A ^a   White, Kimber ^b   Mennear, John H ^c  

^a ISIS PHARMACEUTICALS   (United States)

^b ImmunoTox Inc   (United States)

^c CAMPBELL UNIVERSITY   (United States)

Author keywords

ICAM 1; Immunotoxicology; Mice; Oligonucleotide

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; ALICAFORSEN; ANTISENSE OLIGODEOXYNUCLEOTIDE; BACTERIAL POLYSACCHARIDE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DRUG METABOLITE; GANGLIOSIDE ANTIBODY; GANGLIOTETRAOSYLCERAMIDE ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 6; ISIS 3082; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCING CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CELL ACTIVITY; CELL POPULATION; CELLULAR IMMUNITY; CONTACT SENSITIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG TISSUE LEVEL; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTOXICITY; LYMPHOCYTE COUNT; MITOGENESIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SPLEEN WEIGHT; TOXICITY TESTING;

BACTERIA (MICROORGANISMS); MAMMALIA; MURINAE;

EID: 33845509518     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.1080/15476910601046538     Document Type: Article

References (43)

1. Barish, C. F. 2005. Alicaforsen therapy in inflammatory bowel disease. Expert Opin. Biol. Ther. 5:1387-1391.
2. Bennett, C. F., Kornbrust, D., Henry, S. P., Stecker, K., Howard, R., Cooper, S., Dutson, S., Hall, W., and Jacoby, H. I. 1997. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J. Pharmacol. Exp. Ther. 280:988-1000.
3. Black, L. E., DeGeorge, J. J., Cavagnaro, J. A., Jordan, A., and Ahn, C. 1993. Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs. Antisense Res. Dev. 3:399-404.
4. Black, L. E., Farrelly, J. G., Cavagnaro, J. A., Ahn, C., DeGeorge, J. J., Taylor, A. S., DeFelice, A. F., and Jordan, A. 1994. Regulatory considerations of oligonucleotide drugs: Updated recommendations for pharmacology and toxicology studies. Antisense Res. Dev. 4:299-301.
5. Branda, R. F., Moore, A. L., Hong, R., Mccormack, J. J., Zon, G., and Cunningham-Rundles, C. 1996a. B-Cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. Clin. Immunol. Immunopathol. 79:115-121.
6. Branda, R. F., Moore, A. L., Lafayette, A. R., Mathews, L., Hong, R., Zon, G., Brown, T., and McCormack, J. J. 1996b. Amplification of antibody production by phosphorothioate oligodeoxynucleotides. J. Lab. Clin. Med. 128:329-338.
7. Crooke, S. T. 2004. Antisense strategies. Curr. Mol. Med. 4:465-487.
8. Geary, R. S., Leeds, J. M., Fitchett, J., Burckin, T, Troung, L., Spainhour, C., Creek, M., and Levin, A. A. 1997. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab. Dispos. 25:1272-1281.
9. Gursel, M., Verthelyi, D., Gursel, I., Ishii, K. J., and Klinman, D. M. 2002. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J. Leukocyte Biol. 71:813-820.
10. Hartmann, G., and Krieg, A. M. 1999. CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Therap. 6:893-903.
11. Hartmann, G., Weiner, G. J., and Krieg, A. M. 1999. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 96:9305-9310.
12. Henry, S. P., Monteith, D., Bennett, C. F., and Levin, A. A. 1997a. Toxicological and pharmacokinetic properties of chemically-modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Anticancer Drug Des. 12:409-420.
13. Henry, S. P., Stecker, K., Brooks, D., Monteith, D., Conklin, B., and Bennett, C. F. 2000. Chemically-modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther. 292:468-479.
14. Henry, S. P., Taylor, J., Midgley, L., Levin, A. A., and Kornbrust, D. J. 1997b. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice. Antisense Nucl. Acid Drug Dev. 7:473-481.
15. Jason, T. L., Koropatnick, J., and Berg, R. W. 2004. Toxicology of anti-sense therapeutics. Toxicol. Appl. Pharmacol. 201:66-83.
16. Jerne, N. K., Henry, C., Nordin, A. A., Fuji, H., Koros, A. M., and Lefkovits, I. 1974. Plaque forming cells: Methodology and theory. Transplant Rev 18:130-191.
17. Karikó, K., Ni, H., Capodici, J., Lamphier, M., and Weissman, D. 2004. mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 279:12542-12550.
18. Klinman, D. M. 2004. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4:249-258.
19. Klinman, D. M., Kyung, Y., Beaucage, S. L., Conover, J., and Krieg, A. M. 1996. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin-6, interleukin-12, and interferon-γ. Proc. Natl. Acad. Sci. USA 93:2879-2883.
20. Klinman, D. M., Takeshita, F., Gursel, I., Leifer, C., Ishii, K. J., Verthelyi, D., and Gursel, M. 2002. CpG DNA: Recognition by and activation of monocytes. Microbes Infect. 4:897-901.
21. Krieg, A. M. 1998. Immune stimulation by oligonucleotides. In: Antisense Research and Applications, ed. S. T. Crooke, Berlin: Springer-Verlag.
22. Krieg, A. M. 1999. CpG DNA: A novel immunomodulator. Trends Microbiol 7:64-65.
23. Krieg, A. M. 2000. The role of CpG motifs in innate immunity. Curr. Opin. Immunol. 12:35-43.
24. Krieg, A. M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709-760.
25. Krieg, A. M. 2004. Antitumor applications of stimulating Toll-like receptor 9 with CpG oligodeoxynucleotides. Curr. Oncol. Rep. 6:88-95.
26. Leeds, J. M., Geary, R. S., Henry, S. P., Glover, J., Shanahan, W., Fitchett, J., Burckin, T., Truong, L., and Levin, A. A. 1997. Pharmacokinetic properties of phosphorothioate oligonucleotides. Nucleosides Nucleotides 16:1689-1693.
27. Levin, A. A., Henry, S. P., Monteith, D., and Templin, M. 2001. Toxicity of anti-sense oligonucleotides. In: Antisense Drug Technology, ed. S. T. Crooke, New York: Marcel Dekker.
28. Lund, J. M., Alexopoulou, L., Sato, A., Karow, M., Adams, N. C., Gale, N. W., Iwasaki, A., and Flavell, R. A. 2004. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 101:5598-5603.
29. Luster, M. I., Munson, A. E., Thomas, P. T., Holsapple, M. P., Fenters, J. D., White, K. L., Jr., Lauer, L. D., Germolec, D. R., Rosenthal, G. J., and Dean, J. H. 1988. Development of a testing battery to assess chemical-induced immunotoxicity: National Toxicology Program's guidelines for immunotoxicity evaluation in mice. Fundam. Appl. Toxicol. 10:2-19.
30. Miner, P., Wedel, M., Bane, B., and Bradley, J. 2004. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol. Ther. 19:281-286.
31. Miner, P. B., Jr., Geary, R. S., Matson, J., Chuang, E., Xia, S., Baker, B. F., and Wedel, M. K. 2006. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol. Ther. 23:1427-1434.
32. Senn, J. J., Burel, S., and Henry, S. P. 2005. Non-CpG containing anti-sense 2′ MOE oligonucleotides activate a proinflammatory response independent of TLR-9 or MyD88. J. Pharmacol. Exp. Ther. 314:972-979.
33. Sparwasser, T., Hultner, L., Koch, E. S., Luz, A., Lipford, G. B., and Wagner, H. 1999. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J. Immunol. 162:2368-2374.
34. Stacey, K. J., Young, G. R., Clark, F., Sester, D. P., Roberts, T. L., Naik, S., Sweet, M. J., and Hume, D. A. 2003. The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J. Immunol. 170:3614-3620.
35. Stepkowski, S. M., Wang, M. E., Amante, A., Kalinin, D., Qu, X., Blasdel, T., Condon, T., Kahan, B. D., and Bennett, C. F. 1997. Anti-sense ICAM-1 oligonucleotides block allograft rejection in rats. Transpl. Proc. 29:1285.
36. Takeshita, F., Leifer, C. A., Gursel, I., Ishii, K. J., Takeshita, S., Gursel, M., and Klinman, D. M. 2001. Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 167:3555-3558.
37. Takeshita, S., Takeshita, F., Haddad, D. E., Ishii, K. J., and Klinman, D. M. 2000. CpG oligodeoxynucleotides induce murine macrophages to up-regulate chemokine mRNA expression. Cell. Immunol. 206:101-106.
38. Ulrich, H. 2006. RNA aptamers: From basic science towards therapy. Handbook Exp. Pharmacol. 173:305-326.
39. Verthelyi, D., Ishii, K. J., Gursel, M., Takeshita, F., and Klinman, D. K. 2001. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J. Immunol. 166:2372-2377.
40. Vidal, L., Blagden, S., Attard, G., and de Bono, J. 2005. Making sense of antisense. Eur. J. Cancer 41:2812-2818.
41. Zhao, Q., Temsamani, J., Zhou, R., and Agrawal, S. 1997. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucl. Acid Drug Dev. 7:495-502.
42. Yacyshyn, B. R., Chey, W. Y., Goff, J., Salzberg, B., Baerg, R., Buchman, A. L., Tami, J., Yu, R., Gibiansky, E., and Shanahan, W. R. 2002. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 anti-sense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 51:30-36.
43. Zhou, W., and Agrawal, S. 1998. Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects. Bioorg. Med. Chem. Lett. 8:3269-3274.